HAE
Income statement / Annual
Last year (2025), Haemonetics Corporation's total revenue was $1.36 B,
an increase of 3.95% from the previous year.
In 2025, Haemonetics Corporation's net income was $167.68 M.
See Haemonetics Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
03/29/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
| Operating Revenue |
$1.36 B |
$1.31 B |
$1.17 B |
$993.20 M |
$870.46 M |
$988.48 M |
$967.58 M |
$903.92 M |
$886.12 M |
$908.83 M |
| Cost of Revenue |
$582.28 M
|
$597.14 M
|
$545.79 M
|
$462.43 M
|
$442.02 M
|
$500.66 M
|
$550.04 M
|
$492.02 M
|
$507.62 M
|
$502.92 M
|
| Gross Profit |
$778.55 M
|
$711.92 M
|
$622.87 M
|
$530.77 M
|
$428.45 M
|
$487.82 M
|
$417.54 M
|
$411.91 M
|
$378.49 M
|
$405.91 M
|
| Gross Profit Ratio |
0.57
|
0.54
|
0.53
|
0.53
|
0.49
|
0.49
|
0.43
|
0.46
|
0.43
|
0.45
|
| Research and Development Expenses |
$69.42 M
|
$63.04 M
|
$58.63 M
|
$55.20 M
|
$40.66 M
|
$39.08 M
|
$35.71 M
|
$39.23 M
|
$47.26 M
|
$55.87 M
|
| General & Administrative Expenses |
$414.35 M
|
$413.72 M
|
$366.75 M
|
$327.80 M
|
$261.13 M
|
$262.03 M
|
$293.78 M
|
$313.42 M
|
$299.23 M
|
$313.32 M
|
| Selling & Marketing Expenses |
$7.70 M
|
$7.10 M
|
$7.20 M
|
$4.40 M
|
$2.70 M
|
$4.30 M
|
$4.50 M
|
$3.10 M
|
$2.50 M
|
$3.90 M
|
| Selling, General & Administrative Expenses |
$422.05 M
|
$420.82 M
|
$373.95 M
|
$332.20 M
|
$263.83 M
|
$266.33 M
|
$298.28 M
|
$316.52 M
|
$301.73 M
|
$317.22 M
|
| Other Expenses |
$65.26 M
|
$63.18 M
|
$34.26 M
|
$62.62 M
|
$34.21 M
|
$79.05 M
|
$0.00
|
$0.00
|
$48.89 M
|
$76.77 M
|
| Operating Expenses |
$556.73 M
|
$547.03 M
|
$466.84 M
|
$450.02 M
|
$338.70 M
|
$384.47 M
|
$333.99 M
|
$355.75 M
|
$397.88 M
|
$449.86 M
|
| Cost And Expenses |
$1.14 B
|
$1.14 B
|
$1.01 B
|
$912.45 M
|
$780.72 M
|
$885.13 M
|
$884.03 M
|
$847.77 M
|
$905.50 M
|
$952.77 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$9.75 M
|
$13.02 M
|
$14.63 M
|
$17.12 M
|
$16.83 M
|
$16.20 M
|
$9.91 M
|
$4.53 M
|
$8.10 M
|
$9.47 M
|
| Depreciation & Amortization |
$108.89 M
|
$88.62 M
|
$84.81 M
|
$86.55 M
|
$84.29 M
|
$92.19 M
|
$109.42 M
|
$89.25 M
|
$84.03 M
|
$85.01 M
|
| EBITDA |
$355.99 M |
$295.45 M |
$252.01 M |
$191.72 M |
$184.38 M |
$257.93 M |
$192.96 M |
$153.03 M |
$123.25 M |
$128.74 M |
| EBITDA Ratio |
0.26
|
0.23
|
0.22
|
0.19
|
0.21
|
0.26
|
0.2
|
0.17
|
0.14
|
0.14
|
| Operating Income Ratio |
0.16
|
0.13
|
0.13
|
0.08
|
0.1
|
0.1
|
0.09
|
0.06
|
-0.02
|
-0.05
|
| Total Other Income/Expenses Net |
-$9.75 M
|
-$13.02 M
|
-$14.63 M
|
-$17.12 M
|
-$16.83 M
|
-$16.20 M
|
-$9.91 M
|
$3.48 M
|
-$8.10 M
|
-$9.47 M
|
| Income Before Tax |
$212.07 M
|
$151.87 M
|
$141.40 M
|
$63.63 M
|
$72.91 M
|
$87.15 M
|
$73.63 M
|
$59.63 M
|
-$27.48 M
|
-$53.42 M
|
| Income Before Tax Ratio |
0.16
|
0.12
|
0.12
|
0.06
|
0.08
|
0.09
|
0.08
|
0.07
|
-0.03
|
-0.06
|
| Income Tax Expense |
$44.39 M
|
$34.31 M
|
$26.00 M
|
$20.25 M
|
-$6.56 M
|
$10.63 M
|
$18.61 M
|
$14.06 M
|
-$1.21 M
|
$2.16 M
|
| Net Income |
$167.68 M
|
$117.56 M
|
$115.40 M
|
$43.38 M
|
$79.47 M
|
$76.53 M
|
$55.02 M
|
$45.57 M
|
-$26.27 M
|
-$55.62 M
|
| Net Income Ratio |
0.12
|
0.09
|
0.1
|
0.04
|
0.09
|
0.08
|
0.06
|
0.05
|
-0.03
|
-0.06
|
| EPS |
3.31 |
2.32 |
2.27 |
0.85 |
1.57 |
1.51 |
1.07 |
0.86 |
-0.51 |
-1.09 |
| EPS Diluted |
3.31 |
2.29 |
2.24 |
0.84 |
1.55 |
1.48 |
1.04 |
0.85 |
-0.51 |
-1.09 |
| Weighted Average Shares Out |
$50.33 M
|
$50.71 M
|
$50.78 M
|
$51.05 M
|
$50.69 M
|
$50.69 M
|
$51.53 M
|
$52.76 M
|
$51.51 M
|
$50.91 M
|
| Weighted Average Shares Out Diluted |
$50.73 M
|
$51.40 M
|
$51.42 M
|
$51.35 M
|
$51.29 M
|
$51.82 M
|
$52.94 M
|
$53.50 M
|
$51.52 M
|
$50.91 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
